Current therapies and investigational drugs for peripheral arterial disease

@article{Suzuki2016CurrentTA,
  title={Current therapies and investigational drugs for peripheral arterial disease},
  author={Jun-Ichi Suzuki and Munehisa Shimamura and Hiroyuki Suda and Kouji Wakayama and Hidetoshi Kumagai and Yuichi Ikeda and Hiroshi Akazawa and Mitsuaki Isobe and Issei Komuro and Ryuichi Morishita},
  journal={Hypertension Research},
  year={2016},
  volume={39},
  pages={183-191}
}
Peripheral artery disease (PAD) is associated with elevated morbidity and mortality with cardiovascular (CV) disease. The guideline recommends smoking cessation and antiplatelet/antithrombotic drugs for asymptomatic and symptomatic PAD patients. It also recommends that PAD patients with critical limb ischemia (CLI) should be considered to receive endovascular and open surgical treatment for limb salvage. Although PAD patients with CLI receive these treatments, they are sometimes unable to… Expand
Endothelial Cell-Specific Knockout of Meis1 Protects Ischemic Hindlimb Through Vascular Remodeling
TLDR
This study aims to investigate the role and underlying mechanism of Meis1 in the regulation of arteriogenesis and angiogenesis using hindlimb ischemia model of transgenic neonatal mice and develops a method protocol to identify mice of all ages, especially neonates that faced methodological difficulties to easily and permanently label. Expand
Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option
TLDR
The mounting evidence for the use of ghrelin as a novel therapeutic for critical limb ischemia is focused on, and the miRs which orchestrate these physiological events are highlighted. Expand
Therapeutic strategies for cell-based neovascularization in critical limb ischemia
TLDR
To establish cell-based therapeutic angiogenesis as one of the most promising therapeutic strategies for CLI patients, its advantages and limitations should be taken into account. Expand
Long term outcomes in diabetic patients treated with atherectomy for peripheral artery disease.
TLDR
Plaque modification with adjusted atherectomy appears to have similar outcomes in diabetic as well as in non-diabetic patients, and a randomized study would be warranted to confirm the findings. Expand
Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.
TLDR
Transcutaneous partial pressure of oxygen, C-reative protein and neutrophil content in CTPs are predictive of the clinical outcome at 6 months, and Transcriptomic profiling revealed the strong angiogenic potential of BM-CTPs. Expand
Periodontitis deteriorates peripheral arterial disease in Japanese population via enhanced systemic inflammation
TLDR
It is clarified that PAD patients had decreased tooth number and worsened oral and periodontal condition with enhanced systemic inflammation. Expand
A Swine Hind Limb Ischemia Model Useful for Testing Peripheral Artery Disease Therapeutics
TLDR
A preclinical platform for porcine studies of peripheral artery disease therapies including (1) a hind limb ischemia model and (2) non-invasive MSC viability and retention assessment via PET is established. Expand
Outcomes in Patients with Critical Limb Ischemia due to Arteriosclerosis Obliterans Who Did Not Undergo Arterial Reconstruction.
TLDR
Surgical revascularization did not improve the prognosis of patients with CLI as compared with the conservative therapy, and 77% of patients survived for more than two years after receiving only conservative therapies. Expand
Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan.
TLDR
It is indicated that intramuscular injection of naked HGF plasmid tended to improve the resting pain and significantly decreased the size of the ischemic ulcer in the patients with CLI who did not have any alternative therapy such as endovascular treatment (EVT) or bypass graft surgery. Expand
Oroxylin a Attenuates Limb Ischemia by Promoting Angiogenesis via Modulation of Endothelial Cell Migration
  • Lusha Zhang, Lu Chen, +10 authors Hong Wang
  • Medicine
  • Frontiers in Pharmacology
  • 2021
Oroxylin A (OA) has been shown to simultaneously increase coronary flow and provide a strong anti-inflammatory effect. In this study, we described the angiogenic properties of OA. OA treatmentExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 127 REFERENCES
Medical treatment of peripheral arterial disease: a comprehensive review.
TLDR
The clinical data supporting aggressive medical interventions for patients with PAD, including revascularization and maximal medical therapy for improvement of physical function as well as reduction in risk for subsequent major cardiovascular events are reviewed. Expand
Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50
TLDR
Vorapaxar did not reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with peripheral artery disease; however, vorAPaxar significantly reduced acute limb ischemia and peripheral revascularization. Expand
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
TLDR
In patients with peripheral arterial disease, the combination of an oral anticoagulant and antiplatelet therapy was not more effective than anti platelet therapy alone in preventing major cardiovascular complications and was associated with an increase in life-threatening bleeding. Expand
Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease
TLDR
The aim of this review is to discuss relevant scientific and clinical advances in therapeutic angiogenesis and their potential application in the treatment of ischemic diseases of the peripheral arteries. Expand
Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events
TLDR
Vorapaxar was discontinued in patients with a history of stroke due to excessive risk for intracranial hemorrhage after 2 years of therapy, and as an adjunctive therapy to standard regimens, vorAPaxar provides a greater net clinical benefit in MI patients who are at a lower risk for bleeding. Expand
Medical treatment of critical limb ischemia: current state and future directions.
TLDR
Evidence suggests that prostanoids, dedicated wound care programs, and several mechanical devices, such as spinal cord stimulation, intermittent pneumatic compression, and hyperbaric oxygen therapy, can alleviate ischemic symptoms and improve limb salvage in non-reconstructable patients with stable pain and tissue loss. Expand
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.
TLDR
It is concluded that this small, randomized gene therapy study failed to meet the primary objective of significant amputation reduction, however, significant and meaningful improvement was found in patients treated with a VEGF165-containing plasmid. Expand
Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery Disease
TLDR
Athrosclerotic risk factors are less intensively treated among PAD patients than CAD patients, and a number of possible explanations could account for these disparities in therapeutic intensity. Expand
Long-Term Outcome of Therapeutic Neovascularization Using Peripheral Blood Mononuclear Cells for Limb Ischemia
TLDR
In conclusion, injection of peripheral blood mononuclear cells might be safe and potentially effective for the treatment of limb ischemia, but caution is needed when managing ASO patients on dialysis. Expand
Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease
TLDR
Findings may be cautiously interpreted to indicate that intramuscular injection of naked HGF plasmid is safe, feasible, and can achieve successful improvement of ischemic limbs as sole therapy. Expand
...
1
2
3
4
5
...